Cargando…

Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress

Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Wei, Lam, Yi Hui, Periyasamy, Giridharan, Chuah, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910862/
https://www.ncbi.nlm.nih.gov/pubmed/35270002
http://dx.doi.org/10.3390/ijms23052863
_version_ 1784666599732543488
author Xiang, Wei
Lam, Yi Hui
Periyasamy, Giridharan
Chuah, Charles
author_facet Xiang, Wei
Lam, Yi Hui
Periyasamy, Giridharan
Chuah, Charles
author_sort Xiang, Wei
collection PubMed
description Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients.
format Online
Article
Text
id pubmed-8910862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89108622022-03-11 Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress Xiang, Wei Lam, Yi Hui Periyasamy, Giridharan Chuah, Charles Int J Mol Sci Review Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by extensive heterogeneity in genetics, response to therapy and long-term outcomes, making it a prototype example of development for personalized medicine. Given the accessibility to hematologic malignancy patient samples and recent advances in high-throughput technologies, large amounts of biological data that are clinically relevant for diagnosis, risk stratification and targeted drug development have been generated. Recent studies highlight the potential of implementing genomic-based and phenotypic-based screens in clinics to improve survival in patients with refractory AML. In this review, we will discuss successful applications as well as challenges of most up-to-date high-throughput technologies, including artificial intelligence (AI) approaches, in the development of personalized medicine for AML, and recent clinical studies for evaluating the utility of integrating genomics-guided and drug sensitivity testing-guided treatment approaches for AML patients. MDPI 2022-03-05 /pmc/articles/PMC8910862/ /pubmed/35270002 http://dx.doi.org/10.3390/ijms23052863 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xiang, Wei
Lam, Yi Hui
Periyasamy, Giridharan
Chuah, Charles
Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title_full Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title_fullStr Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title_full_unstemmed Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title_short Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
title_sort application of high throughput technologies in the development of acute myeloid leukemia therapy: challenges and progress
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910862/
https://www.ncbi.nlm.nih.gov/pubmed/35270002
http://dx.doi.org/10.3390/ijms23052863
work_keys_str_mv AT xiangwei applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress
AT lamyihui applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress
AT periyasamygiridharan applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress
AT chuahcharles applicationofhighthroughputtechnologiesinthedevelopmentofacutemyeloidleukemiatherapychallengesandprogress